Dana Flanders
Stock Analyst at Guggenheim
(n/a)
# 4,650
Out of 4,820 analysts
9
Total ratings
n/a
Success rate
-25.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dana Flanders
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VALN Valneva SE | Maintains: Buy | $17 → $15 | $7.03 | +113.37% | 1 | Mar 24, 2025 | |
| SCYX SCYNEXIS | Initiates: Buy | $25 | $1.02 | +2,350.98% | 1 | Jan 22, 2021 | |
| PCRX Pacira BioSciences | Initiates: Neutral | n/a | $25.72 | - | 1 | May 27, 2020 | |
| HRTX Heron Therapeutics | Initiates: Buy | $24 | $2.30 | +943.48% | 1 | May 27, 2020 | |
| COLL Collegium Pharmaceutical | Initiates: Neutral | n/a | $26.57 | - | 1 | May 27, 2020 | |
| LGND Ligand Pharmaceuticals | Initiates: Neutral | n/a | $107.70 | - | 2 | Mar 10, 2020 | |
| EBS Emergent BioSolutions | Upgrades: Buy | $60 → $75 | $5.47 | +1,271.12% | 2 | Nov 2, 2018 |
Valneva SE
Mar 24, 2025
Maintains: Buy
Price Target: $17 → $15
Current: $7.03
Upside: +113.37%
SCYNEXIS
Jan 22, 2021
Initiates: Buy
Price Target: $25
Current: $1.02
Upside: +2,350.98%
Pacira BioSciences
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $25.72
Upside: -
Heron Therapeutics
May 27, 2020
Initiates: Buy
Price Target: $24
Current: $2.30
Upside: +943.48%
Collegium Pharmaceutical
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $26.57
Upside: -
Ligand Pharmaceuticals
Mar 10, 2020
Initiates: Neutral
Price Target: n/a
Current: $107.70
Upside: -
Emergent BioSolutions
Nov 2, 2018
Upgrades: Buy
Price Target: $60 → $75
Current: $5.47
Upside: +1,271.12%